Inherited disorders of trafficking

Whole Genome Sequencing Market Size, Share & Trends Analysis Report By Product, By Type, By Workflow, By Application, By End-use, By Region And Segment Forecasts, 2023 - 2030

Retrieved on: 
Tuesday, March 14, 2023
Drug development, Workflow, QIAGEN, Whole genome sequencing, Government, Infection, WGS, Prevalence, FDA, SARS-CoV-2, PFGE, The New England Journal of Medicine, Myenteric plexus, Mark R. Dybul, TB, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Cancer, Human, Growth, COVID-19, Rare, Medicine, DSM-IV codes, Inherited disorders of trafficking, Application, Research, Disorder, Food and Drug Administration, Diagnosis, Tuberculosis, USD, Drug resistance, Ill, Pharmaceutical industry, Vaccine, Antibiotics

The market growth can be attributed to the rising adoption of whole genome sequencing for genome mapping programs and the increasing prevalence of inherited disorders, including rare genetic disorders.

Key Points: 
  • The market growth can be attributed to the rising adoption of whole genome sequencing for genome mapping programs and the increasing prevalence of inherited disorders, including rare genetic disorders.
  • Furthermore, the growing investment in R&D for the early detection and treatment of disorders with the aid of WGS is expected to propel the growth of the market.
  • Whole genome sequencing has a wide range of applications, and government bodies are adopting these technologies for sequencing the genomes of humans, plant, animal, and microbes, which is expected to drive market growth.
  • For instance, U.S. Food & Drug Administration (FDA) adopted the method to identify foodborne pathogens during foodborne disease outbreaks across the countries.

Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth

Retrieved on: 
Sunday, December 11, 2022
Research, Parenting, Baby, Maternity, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Other Science, Intracranial hemorrhage, Phase, Arm, Leg, Lung, Ixa, Factor, Female, Thrombotic microangiopathy, Haemophilia, Inherited disorders of trafficking, Life, Protein, Skin, APCC, Society, TMA, ABR, Patient, Blood, RO, HAVEN, Parent, Bleeding, AE, Woman, World government, Quality of life, ROG, Caregiver, Clinical trial, VIII, Safety, Brain, Hoffmann-La Roche, Pharmacokinetics, World Federation of Hemophilia, Trauma, AES, ASH, Factor X, Risk, Birth control, Pharmaceutical industry, Emicizumab, Genentech

The new data were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans from December 10-13, 2022.

Key Points: 
  • The new data were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans from December 10-13, 2022.
  • Hemlibra provides a flexible treatment option that can be administered subcutaneously from birth at different dosing frequencies.
  • HAVEN 7 is a Phase III, multi-center, open-label study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of Hemlibra in infants with severe hemophilia A without factor VIII inhibitors.
  • Genentech also presented data from the European Haemophilia Safety Surveillance (EUHASS) database and the prospective observational ATHN 7 study at ASH 2022.

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

Retrieved on: 
Wednesday, November 30, 2022
Marketing, COVID-19, Growth, EST, COVID-19 testing, Dana–Farber Cancer Institute, OTC, Polymerase chain reaction, Laboratory, Chromosome, Food, Genomics, Gene, DNA, Indian stock exchange, Institution, Prophase, PIM, Inherited disorders of trafficking, CLIA, University, PCR, Planet, Dietary supplement, FDM, Nebula Genomics, Dana, Research, RT-PCR, Severe acute respiratory syndrome coronavirus 2, LB-1, Acquisition, TK, Video game, Vaccine

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.

Key Points: 
  • GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.
  • The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.

Genomics Global Market Report 2022: Increasing Demand for Novel Therapeutics Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Biotechnology, Genetics, Health, Genetic Alliance, Genetic disorder, Genomics, Molecular epidemiology, Infection, IHOP, Government, CDC, Cancer, Severe acute respiratory syndrome coronavirus 2, National Cancer Institute, University of Cambridge, Survivor, Biomarker, Functional genomics, USD, Biomarker discovery, Research, CRISPR, Pathway analysis, Nature, Chromosome, Metagenomics, National Centre for Disease Control, Disease, Whole genome sequencing, Therapy, Degenerative disease, Inherited disorders of trafficking, NGS, Illumina, Inc., Merck & Co., OGL, Gene, Antibiotics, Epigenomics

The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global genomics market size is expected to reach USD 94.9 billion by 2030.
  • The market is expected to register a CAGR of 16.4% in the forecast period owing to the increasing demand for novel therapeutics and research applications in genomics.
  • Functional genomics held the largest market share in the year 2021, owing to the demand for rising applications in diagnostics and gene therapy.

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Retrieved on: 
Monday, November 14, 2022
FDA, Other Health, Pharmaceutical, General Health, Medical Devices, Parenting, Children, Baby, Maternity, Family, Science, Biotechnology, Consumer, Other Science, Health, Research, Automation, FDA, Brainstem, Spinal muscular atrophy, Marketing, SCID, ESG, Food, Accreditation, Laboratory, Government, PerkinElmer, CE, PCR, DNA, Reproductive health, NYSE, Science, Motor neuron, SMA, Infant, Spinal cord, Software, Safety, Fundamental Analysis Software, Informatics, IVD, Birth, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PKI, Degenerative disease, Inherited disorders of trafficking, Muscle weakness, Atrophy, Pharmaceutical industry

This is the first FDA authorized assay for SMA screening in newborns in the United States and is part of the Companys broader EONIS Platform .

Key Points: 
  • This is the first FDA authorized assay for SMA screening in newborns in the United States and is part of the Companys broader EONIS Platform .
  • This authorization is a major milestone for newborn screening in the United States.
  • Other components of the platform include the EONIS DNA Extraction kit and EONIS Analysis Software.
  • As the global leader in newborn screening, PerkinElmer offers solutions to help identify more than 50 congenital disorders.

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

Retrieved on: 
Tuesday, November 8, 2022
PCR, Medical physics, Research, Department, Gene, Dana–Farber Cancer Institute, Nature, LB-1, Radiation therapy, Company, Industry, Marketing, Dana, Dietary supplement, Environment, SEC, Cancer, Polymerase chain reaction, Acquisition, RT-PCR, COVID-19, Chromosome, CLIA, Private Securities Litigation Reform Act, Inherited disorders of trafficking, Prophase, Nasdaq, Vegetable, Linebacker, Polyphenol, Dementia, Harvard Medical School, Media relations, FDM, Nano, PIM, Toxicity, Growth, Memory, Central nervous system, Food, Trial of the century, GLOBE, Genomics, University, TK, Laboratory, OTC, Severe acute respiratory syndrome coronavirus 2, Labs, Risk, Nebula Genomics, COVID-19 testing, DNA, NASDAQ, Nano Letters, Publication, Myricetin, Inflammation, Pharmaceutical industry, Medical device, Medicinal plants, MD, Brigham

This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.

Key Points: 
  • This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.
  • ProPhase Labs is eager to explore new avenues for scientific discovery with these talented scientists as we pursue novel pathways for cancer treatment.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.
  • The company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co-therapy.

ProPhase Labs to Present at Investor Summit Group’s Q4 Conference

Retrieved on: 
Tuesday, November 8, 2022
Sheraton New York Times Square Hotel, Chromosome, CLIA, Genomics, University, TK, Laboratory, Marketing, PCR, Inherited disorders of trafficking, OTC, Prophase, Severe acute respiratory syndrome coronavirus 2, Dietary supplement, Nasdaq, Research, Nebula Genomics, Gene, COVID-19 testing, LB-1, Seventh Avenue, DNA, LB-2, FDM, PIM, Company, Food, Acquisition, RT-PCR, COVID-19, Fine chemical, Vaccine

ET

Key Points: 
  • ET
    Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York,
    The conference is completely complimentary to qualified investors.
  • Please register at Complimentary I n vestor Registr a tion
    ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.
  • ProPhase Diagnostics also offers rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase Labs actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.

Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

Retrieved on: 
Tuesday, November 8, 2022
Review, B cell, Biomedical engineering, UCLA, Developmental Biology (journal), Health, MD, Bachelor of Engineering, Systems biology, Biotechnology, Cancer, Stem cell, Mesoderm, Molecular genetics, Hannover Medical School, GMP, Placenta, CAR, SAB, IPSC, University, Synthetic biology, Doctor of Philosophy, University of Toronto, Inherited disorders of trafficking, Biomedicine, HSC, United States Air Force Scientific Advisory Board, University of Wisconsin–Madison, Genome, Cell, Research, Therapy, Tumor microenvironment, CD34, Developmental biology, Automation, CEO, Management, Vaccine, BC, Microbiology, Notch, Immunology

VANCOUVER, BC, Nov. 8, 2022 /PRNewswire/ -- Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to welcome new members to its Scientific Advisory Board (SAB). Joining existing SAB members—Peter Zandstra, PhD; Juan Carlos Zúñiga-Pflücker, PhD; and Yvonne Chen, PhD—are Kris Saha, PhD; Hanna Mikkola, MD, PhD; and Robert Zweigerdt, PhD; who will review and provide input, opinion, and expertise into Notch's research endeavors. Notch thanks outgoing SAB members Chris Sturgeon, PhD; Marcel van den Brink, MD, PhD; and Jeff Hubbell, PhD for their contributions.

Key Points: 
  • Notch thanks outgoing SAB members Chris Sturgeon, PhD; Marcel van den Brink, MD, PhD; and Jeff Hubbell, PhD for their contributions.
  • "Notch's leadership team, at every level, comprises some of the best minds in preclinical science, advanced cell manufacturing, bioengineering, and systems biology," observes David Main, Notch's President and CEO.
  • "The members of our SAB are working at the frontiers of scientific and technology discovery, responding to unique, complex challenges that are highly relevant to our work at Notch.
  • Learn more at http://yvchen.bol.ucla.edu/
    Hanna Mikkola, MD, PhD | Professor of Molecular, Cell, and Developmental Biology, UCLA:Dr. Mikkola's research focuses on the microenvironmental cues driving blood lineage development.

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time

Retrieved on: 
Friday, November 4, 2022
Severe acute respiratory syndrome coronavirus 2, Company, Chromosome, DNA, PCR, Research, OTC, PIM, RT-PCR, FDM, COVID-19, Nasdaq, Marketing, LB-1, Nebula Genomics, LB-2, Food, Prophase, TK, Inherited disorders of trafficking, CLIA, Dietary supplement, Acquisition, Genomics, Gene, University, COVID-19 testing, Laboratory, Fine chemical, Vaccine

ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.

Key Points: 
  • ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.
  • The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing.
  • Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results.
  • ProPhase Diagnostics also offers rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

Dr Amit Kakar joins MedGenome Board of Directors

Retrieved on: 
Wednesday, November 2, 2022
Health technology, Awareness, Growth, LeapFrog Investments, Board of directors, Software as a service, Hospital, Clinical research, Genomics, Research, Board, LeapFrog Enterprises, Industry, GE Healthcare, R, Head, Sequoia Capital, Drug discovery, Avenue Capital Group, Business, Novo Nordisk Foundation, Group, Genetic testing, Midsayap Diagnostic Center and Hospital, ESCO, Patient, Novo, Genome, Hospital Insurance and Diagnostic Services Act, Inherited disorders of trafficking, Novo Holdings A/S, Global health, Partnership, Solution, Pharmaceutical industry, Management, Biotechnology

The company has announced the appointment of Dr. Amit Kakar MD, from Novo Holdings to its Board of Directors.

Key Points: 
  • The company has announced the appointment of Dr. Amit Kakar MD, from Novo Holdings to its Board of Directors.
  • Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Asiasaid, "MedGenome's journey in the field of genomics has been very impressive.
  • "In embarking on the next phase of our journey, we are delighted to have Dr. Amit and Navjeewan on board.
  • Dr. Amit's experience will help us advance our global expansion plans," said Dr. Felix Olale, Chairman of MedGenome's Board of Directors, and Global Co-Lead for Healthcare Investments at LeapFrog Investments.